Base de dados : MEDLINE
Pesquisa : D20.215.894.899.120 [Categoria DeCS]
Referências encontradas : 231 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 24 ir para página                         

  1 / 231 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28989096
[Au] Autor:Wussow F; Chiuppesi F; Meng Z; Martinez J; Nguyen J; Barry PA; Diamond DJ
[Ad] Endereço:Department of Experimental Therapeutics, Beckman Research Institute of the City of Hope, Duarte, CA, USA. Electronic address: fwussow@coh.org.
[Ti] Título:Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex.
[So] Source:J Virol Methods;251:30-37, 2018 Jan.
[Is] ISSN:1879-0984
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Neutralizing antibodies (NAb) interfering with glycoprotein complex-mediated virus entry into host cells are thought to contribute to the protection against herpesvirus infection. However, using herpesvirus glycoprotein complexes as vaccine antigens can be complicated by the necessity of expressing multiple subunits simultaneously to allow efficient complex assembly and formation of conformational NAb epitopes. By using a novel bacterial artificial chromosome (BAC) clone of the clinically deployable Modified Vaccinia Ankara (MVA) vector and exploiting ribosomal skipping mediated by 2A peptides, MVA vectors were generated that expressed self-processing subunits of the human cytomegalovirus (HCMV) pentamer complex (PC) composed of gH, gL, UL128, UL130, and UL131A. These MVA vectors expressed 2A-linked HCMV PC subunits that were efficiently cleaved and transported to the cell surface as protein complexes forming conformational neutralizing epitopes. In addition, vaccination of mice by only two immunizations with these MVA vectors resulted in potent HCMV NAb responses that remained stable over a period of at least six months. This method of eliciting NAb by 2A-linked, self-processing HCMV PC subunits could contribute to develop a HCMV vaccine candidate and may serve as a template to facilitate the development of subunit vaccine strategies against other herpesviruses.
[Mh] Termos MeSH primário: Anticorpos Neutralizantes/sangue
Anticorpos Antivirais/sangue
Antígenos Virais/imunologia
Vacinas contra Citomegalovirus/imunologia
Citomegalovirus/imunologia
Glicoproteínas/imunologia
Proteínas Estruturais Virais/imunologia
[Mh] Termos MeSH secundário: Animais
Antígenos Virais/genética
Citomegalovirus/genética
Vacinas contra Citomegalovirus/administração & dosagem
Vacinas contra Citomegalovirus/genética
Vetores Genéticos
Glicoproteínas/genética
Esquemas de Imunização
Camundongos
Vacinas Sintéticas/administração & dosagem
Vacinas Sintéticas/genética
Vacinas Sintéticas/imunologia
Vírus Vaccinia/genética
Proteínas Estruturais Virais/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Antigens, Viral); 0 (Cytomegalovirus Vaccines); 0 (Glycoproteins); 0 (Vaccines, Synthetic); 0 (Viral Structural Proteins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171010
[St] Status:MEDLINE


  2 / 231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28854233
[Au] Autor:Bootz A; Karbach A; Spindler J; Kropff B; Reuter N; Sticht H; Winkler TH; Britt WJ; Mach M
[Ad] Endereço:Virologisches Institut, Klinische und Molekulare Virologie, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
[Ti] Título:Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus.
[So] Source:PLoS Pathog;13(8):e1006601, 2017 Aug.
[Is] ISSN:1553-7374
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Human cytomegalovirus (HCMV) is an important, ubiquitous pathogen that causes severe clinical disease in immunocompromised individuals, such as organ transplant recipients and infants infected in utero. Antiviral chemotherapy remains problematic due to toxicity of the available compounds and the emergence of viruses resistant to available antiviral therapies. Antiviral antibodies could represent a valuable alternative strategy to limit the clinical consequences of viral disease in patients. The envelope glycoprotein B (gB) of HCMV is a major antigen for the induction of virus neutralizing antibodies. However, the role of anti-gB antibodies in the course of the infection in-vivo remains unknown. We have used a murine CMV (MCMV) model to generate and study a number of anti-gB monoclonal antibodies (mAbs) with differing virus-neutralizing capacities. The mAbs were found to bind to similar antigenic structures on MCMV gB that are represented in HCMV gB. When mAbs were used in immunodeficient RAG-/- hosts to limit an ongoing infection we observed a reduction in viral load both with mAbs having potent neutralizing capacity in-vitro as well as mAbs classified as non-neutralizing. In a therapeutic setting, neutralizing mAbs showed a greater capacity to reduce the viral burden compared to non-neutralizing antibodies. Efficacy was correlated with sustained concentration of virus neutralizing mAbs in-vivo rather than their in-vitro neutralizing capacity. Combinations of neutralizing mAbs further augmented the antiviral effect and were found to be as potent in protection as polyvalent serum from immune animals. Prophylactic administration of mAbs before infection was also protective and both neutralizing and non-neutralizing mAbs were equally effective in preventing lethal infection of immunodeficient mice. In summary, our data argue that therapeutic application of potently neutralizing mAbs against gB represent a strategy to modify the outcome of CMV infection in immunodeficient hosts. When present before infection, both neutralizing and non-neutralizing anti-gB exhibited protective capacity.
[Mh] Termos MeSH primário: Anticorpos Neutralizantes/imunologia
Anticorpos Antivirais/imunologia
Vacinas contra Citomegalovirus/imunologia
Proteínas do Envelope Viral/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Monoclonais/imunologia
Citomegalovirus/imunologia
Infecções por Citomegalovirus/imunologia
Modelos Animais de Doenças
Camundongos
Reação em Cadeia da Polimerase em Tempo Real
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Cytomegalovirus Vaccines); 0 (Viral Envelope Proteins); 0 (glycoprotein B, Simplexvirus)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170831
[St] Status:MEDLINE
[do] DOI:10.1371/journal.ppat.1006601


  3 / 231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28566275
[Au] Autor:Murray SE; Nesterenko PA; Vanarsdall AL; Munks MW; Smart SM; Veziroglu EM; Sagario LC; Lee R; Claas FHJ; Doxiadis IIN; McVoy MA; Adler SP; Hill AB
[Ad] Endereço:Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR.
[Ti] Título:Fibroblast-adapted human CMV vaccines elicit predominantly conventional CD8 T cell responses in humans.
[So] Source:J Exp Med;214(7):1889-1899, 2017 Jul 03.
[Is] ISSN:1540-9538
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cytomegalovirus (CMV)-based vaccines have shown remarkable efficacy in the rhesus macaque model of acquired immune deficiency syndrome, enabling 50% of vaccinated monkeys to clear a subsequent virulent simian immunodeficiency virus challenge. The protective vaccine elicited unconventional CD8 T cell responses that were entirely restricted by MHC II or the nonclassical MHC I molecule, MHC-E. These unconventional responses were only elicited by a fibroblast-adapted rhesus CMV vector with limited tissue tropism; a repaired vector with normal tropism elicited conventional responses. Testing whether these unusual protective CD8 T responses could be elicited in humans requires vaccinating human subjects with a fibroblast-adapted mutant of human CMV (HCMV). In this study, we describe the CD8 T cell responses of human subjects vaccinated with two fibroblast-adapted HCMV vaccines. Most responses were identified as conventional classically MHC I restricted, and we found no evidence for MHC II or HLA-E restriction. These results indicate that fibroblast adaptation alone is unlikely to explain the unconventional responses observed in macaques.
[Mh] Termos MeSH primário: Linfócitos T CD8-Positivos/imunologia
Infecções por Citomegalovirus/imunologia
Vacinas contra Citomegalovirus/imunologia
Citomegalovirus/imunologia
Fibroblastos/imunologia
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Linhagem Celular
Linhagem Celular Tumoral
Células Cultivadas
Citomegalovirus/fisiologia
Infecções por Citomegalovirus/prevenção & controle
Infecções por Citomegalovirus/virologia
Vacinas contra Citomegalovirus/administração & dosagem
Vacinas contra Citomegalovirus/genética
Epitopos/imunologia
Fibroblastos/virologia
Citometria de Fluxo
Antígenos de Histocompatibilidade Classe I/imunologia
Interações Hospedeiro-Patógeno/efeitos dos fármacos
Interações Hospedeiro-Patógeno/imunologia
Seres Humanos
Células K562
Leucócitos Mononucleares/imunologia
Leucócitos Mononucleares/virologia
Masculino
Microscopia de Fluorescência
Mutação
Vacinação
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cytomegalovirus Vaccines); 0 (Epitopes); 0 (Histocompatibility Antigens Class I)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170602
[St] Status:MEDLINE
[do] DOI:10.1084/jem.20161988


  4 / 231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28490582
[Au] Autor:Britt WJ
[Ad] Endereço:Departments of Pediatrics, Microbiology, and Neurobiology, University of Alabama School of Medicine, Birmingham, Alabama, USA wbritt@peds.uab.edu.
[Ti] Título:Congenital Human Cytomegalovirus Infection and the Enigma of Maternal Immunity.
[So] Source:J Virol;91(15), 2017 Aug 01.
[Is] ISSN:1098-5514
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Human cytomegalovirus (HCMV) is the most common viral infection acquired by the developing human fetus and can result in damage to the developing central nervous system. Although vaccine development to modify this congenital infection is ongoing, the unique epidemiology of maternal HCMV infections appears discordant with strategies for vaccine development. Several characteristics of congenital HCMV infections suggest that the efficacy of vaccines designed to induce responses similar to those that follow natural infection will be limited.
[Mh] Termos MeSH primário: Infecções por Citomegalovirus/congênito
Infecções por Citomegalovirus/imunologia
Transmissão Vertical de Doença Infecciosa/prevenção & controle
Complicações Infecciosas na Gravidez/imunologia
[Mh] Termos MeSH secundário: Infecções por Citomegalovirus/transmissão
Vacinas contra Citomegalovirus/imunologia
Feminino
Seres Humanos
Gravidez
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cytomegalovirus Vaccines)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170726
[Lr] Data última revisão:
170726
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170512
[St] Status:MEDLINE


  5 / 231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28161964
[Au] Autor:Sabbaghian E; Roodbari F; Amani J; Rafiei A
[Ti] Título:In vitro evaluation of a polytope DNA construct as a novel DNA vaccine strategy against human cytomegalovirus-associated diseases.
[So] Source:Acta Virol;61(1):97-104, 2017.
[Is] ISSN:0001-723X
[Cp] País de publicação:Slovakia
[La] Idioma:eng
[Ab] Resumo:Human cytomegalovirus (HCMV) establishes severe disease in fetus, newborn and immunocompromised individuals. Polytope DNA vaccine strategy allows us to choose conserved and immunodominant epitopes from different antigens that can stimulate cellular and humoral immune responses simultaneously. In this study, a synthetic chimeric gene fragment was subcloned in to DNA vaccine vector pcDNA3.1+. The recombinant vector was transferred in to suitable eukaryotic cell line HEK 293T and the expression level of polytope construct from HEK 293T-infected cells was determined by western blot. These results show that there was no mutantion in target segment and recombinant vector showed significant levels of expression. Base on these results, using a proper procedure for design can cause expression and stability of polytope peptide.
[Mh] Termos MeSH primário: Infecções por Citomegalovirus/prevenção & controle
Vacinas contra Citomegalovirus/imunologia
[Mh] Termos MeSH secundário: Clonagem Molecular
DNA Viral/imunologia
Células HEK293
Seres Humanos
Plasmídeos
Vacinas de DNA/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cytomegalovirus Vaccines); 0 (DNA, Viral); 0 (Vaccines, DNA)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170629
[Lr] Data última revisão:
170629
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170207
[St] Status:MEDLINE
[do] DOI:10.4149/av_2017_01_97


  6 / 231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27795304
[Au] Autor:Bernstein DI
[Ad] Endereço:Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA david.bernstein@cchmc.org.
[Ti] Título:Congenital Cytomegalovirus: a "Now" Problem-No Really, Now.
[So] Source:Clin Vaccine Immunol;24(1), 2017 01.
[Is] ISSN:1556-679X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Despite the clear need, progress toward a vaccine for congenital cytomegalovirus (CMV) has been slow. However, recent events have provided new interest, and several vaccine candidates are either in clinical trials or the trials are close to starting. In this issue of Clinical and Vaccine Immunology, Schleiss and colleagues show that a nonreplicating lymphocytic choriomeningitis virus (rLCMV)-vectored vaccine expressing CMV glycoprotein B (gB) and/or pp65 induces B and T cells and improves pup survival in a guinea pig model of congenital CMV infection (Clin Vaccine Immunol 24:e00300-16, 2017, https://doi.org/10.1128/CVI.00300-16). The combination vaccine appeared to be the most effective.
[Mh] Termos MeSH primário: Vacinas contra Citomegalovirus/imunologia
Citomegalovirus/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Antivirais
Infecções por Citomegalovirus/congênito
Cobaias
Seres Humanos
Vacinas Combinadas
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Cytomegalovirus Vaccines); 0 (Vaccines, Combined)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170921
[Lr] Data última revisão:
170921
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161101
[St] Status:MEDLINE


  7 / 231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27795301
[Au] Autor:Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
[Ad] Endereço:Center for Infectious Diseases and Microbiology Translational Research and Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA schleiss@umn.edu.
[Ti] Título:Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
[So] Source:Clin Vaccine Immunol;24(1), 2017 Jan.
[Is] ISSN:1556-679X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Subunit vaccines for prevention of congenital cytomegalovirus (CMV) infection based on glycoprotein B (gB) and pp65 are in clinical trials, but it is unclear whether simultaneous vaccination with both antigens enhances protection. We undertook evaluation of a novel bivalent vaccine based on nonreplicating lymphocytic choriomeningitis virus (rLCMV) vectors expressing a cytoplasmic tail-deleted gB [gB(dCt)] and full-length pp65 from human CMV in mice. Immunization with the gB(dCt) vector alone elicited a comparable gB-binding antibody response and a superior neutralizing response to that elicited by adjuvanted subunit gB. Immunization with the pp65 vector alone elicited robust T cell responses. Comparable immunogenicity of the combined gB(dCt) and pp65 vectors with the individual monovalent formulations was demonstrated. To demonstrate proof of principle for a bivalent rLCMV-based HCMV vaccine, the congenital guinea pig cytomegalovirus (GPCMV) infection model was used to compare rLCMV vectors encoding homologs of pp65 (GP83) and gB(dCt), alone and in combination versus Freund's adjuvanted recombinant gB. Both vectors elicited significant immune responses, and no loss of gB immunogenicity was noted with the bivalent formulation. Combined vaccination with rLCMV-vectored GPCMV gB(dCt) and pp65 (GP83) conferred better protection against maternal viremia than subunit or either monovalent rLCMV vaccine. The bivalent vaccine also was significantly more effective in reducing pup mortality than the monovalent vaccines. In summary, bivalent vaccines with rLCMV vectors expressing gB and pp65 elicited potent humoral and cellular responses and conferred protection in the GPCMV model. Further clinical trials of LCMV-vectored HCMV vaccines are warranted.
[Mh] Termos MeSH primário: Infecções por Citomegalovirus/prevenção & controle
Vacinas contra Citomegalovirus/imunologia
Portadores de Fármacos
Vírus da Coriomeningite Linfocítica/genética
Fosfoproteínas/imunologia
Proteínas do Envelope Viral/imunologia
Proteínas da Matriz Viral/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Neutralizantes/sangue
Anticorpos Antivirais/sangue
Antígenos Virais/genética
Antígenos Virais/imunologia
Infecções por Citomegalovirus/congênito
Vacinas contra Citomegalovirus/administração & dosagem
Modelos Animais de Doenças
Feminino
Cobaias
Camundongos Endogâmicos C57BL
Fosfoproteínas/genética
Linfócitos T/imunologia
Vacinas Combinadas/administração & dosagem
Vacinas Combinadas/imunologia
Vacinas Sintéticas/administração & dosagem
Vacinas Sintéticas/imunologia
Proteínas do Envelope Viral/genética
Proteínas da Matriz Viral/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Antigens, Viral); 0 (Cytomegalovirus Vaccines); 0 (Drug Carriers); 0 (Phosphoproteins); 0 (Vaccines, Combined); 0 (Vaccines, Synthetic); 0 (Viral Envelope Proteins); 0 (Viral Matrix Proteins); 0 (cytomegalovirus matrix protein 65kDa); 0 (glycoprotein B, Simplexvirus)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161101
[St] Status:MEDLINE


  8 / 231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:27760761
[Au] Autor:La Rosa C; Longmate J; Martinez J; Zhou Q; Kaltcheva TI; Tsai W; Drake J; Carroll M; Wussow F; Chiuppesi F; Hardwick N; Dadwal S; Aldoss I; Nakamura R; Zaia JA; Diamond DJ
[Ad] Endereço:Department of Experimental Therapeutics and.
[Ti] Título:MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults.
[So] Source:Blood;129(1):114-125, 2017 Jan 05.
[Is] ISSN:1528-0020
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Attenuated poxvirus modified vaccinia Ankara (MVA) is a useful viral-based vaccine for clinical investigation, because of its excellent safety profile and property of inducing potent immune responses against recombinant (r) antigens. We developed Triplex by constructing an rMVA encoding 3 immunodominant cytomegalovirus (CMV) antigens, which stimulates a host antiviral response: UL83 (pp65), UL123 (IE1-exon4), and UL122 (IE2-exon5). We completed the first clinical evaluation of the Triplex vaccine in 24 healthy adults, with or without immunity to CMV and vaccinia virus (previous DryVax smallpox vaccination). Three escalating dose levels (DL) were administered IM in 8 subjects/DL, with an identical booster injection 28 days later and 1-year follow-up. Vaccinations at all DL were safe with no dose-limiting toxicities. No vaccine-related serious adverse events were documented. Local and systemic reactogenicity was transient and self-limiting. Robust, functional, and durable Triplex-driven expansions of CMV-specific T cells were detected by measuring T-cell surface levels of 4-1BB (CD137), binding to CMV-specific HLA multimers, and interferon-γ production. Marked and durable CMV-specific T-cell responses were also detected in Triplex-vaccinated CMV-seronegatives, and in DryVax-vaccinated subjects. Long-lived memory effector phenotype, associated with viral control during CMV primary infection, was predominantly found on the membrane of CMV-specific and functional T cells, whereas off-target vaccine responses activating memory T cells from the related herpesvirus Epstein-Barr virus remained undetectable. Combined safety and immunogenicity results of MVA in allogeneic hematopoietic stem cell transplant (HCT) recipients and Triplex in healthy adults motivated the initiation of a placebo-controlled multicenter trial of Triplex in HCT patients. This trial was registered at www.clinicaltrials.gov as #NCT02506933.
[Mh] Termos MeSH primário: Antígenos Virais/imunologia
Vacinas contra Citomegalovirus/imunologia
Ativação Linfocitária/imunologia
Linfócitos T/imunologia
[Mh] Termos MeSH secundário: Adulto
Citomegalovirus
Vacinas contra Citomegalovirus/efeitos adversos
Feminino
Seres Humanos
Proteínas Imediatamente Precoces/imunologia
Masculino
Meia-Idade
Fosfoproteínas/imunologia
Transativadores/imunologia
Proteínas da Matriz Viral/imunologia
Vacinas Virais
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Viral); 0 (Cytomegalovirus Vaccines); 0 (IE1 protein, cytomegalovirus); 0 (IE2 protein, Cytomegalovirus); 0 (Immediate-Early Proteins); 0 (MVA vaccine); 0 (Phosphoproteins); 0 (Trans-Activators); 0 (Viral Matrix Proteins); 0 (Viral Vaccines); 0 (cytomegalovirus matrix protein 65kDa)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161021
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1182/blood-2016-07-729756


  9 / 231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27907183
[Au] Autor:Tomic A; Varanasi PR; Golemac M; Malic S; Riese P; Borst EM; Mischak-Weissinger E; Guzmán CA; Krmpotic A; Jonjic S; Messerle M
[Ad] Endereço:Institute of Virology, Hannover Medical School, Hannover, Germany.
[Ti] Título:Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D Ligand.
[So] Source:PLoS Pathog;12(12):e1006015, 2016 Dec.
[Is] ISSN:1553-7374
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Development of an effective vaccine against human cytomegalovirus (HCMV) is a need of utmost medical importance. Generally, it is believed that a live attenuated vaccine would best provide protective immunity against this tenacious pathogen. Here, we propose a strategy for an HCMV vaccine that aims at the simultaneous activation of innate and adaptive immune responses. An HCMV strain expressing the host ligand ULBP2 for the NKG2D receptor was found to be susceptible to control by natural killer (NK) cells, and preserved the ability to stimulate HCMV-specific T cells. Infection with the ULBP2-expressing HCMV strain caused diminished cell surface levels of MHC class I molecules. While expression of the NKG2D ligand increased the cytolytic activity of NK cells, NKG2D engagement in CD8+ T cells provided co-stimulation and compensated for lower MHC class I expression. Altogether, our data indicate that triggering of both arms of the immune system is a promising approach applicable to the generation of a live attenuated HCMV vaccine.
[Mh] Termos MeSH primário: Imunidade Adaptativa/imunologia
Infecções por Citomegalovirus/imunologia
Vacinas contra Citomegalovirus/imunologia
Imunidade Inata/imunologia
Peptídeos e Proteínas de Sinalização Intercelular/imunologia
[Mh] Termos MeSH secundário: Animais
Citomegalovirus/imunologia
Modelos Animais de Doenças
Ensaio de Imunoadsorção Enzimática
Citometria de Fluxo
Proteínas Ligadas por GPI/imunologia
Seres Humanos
Imuno-Histoquímica
Células Matadoras Naturais/imunologia
Ligantes
Camundongos
Reação em Cadeia da Polimerase em Tempo Real
Vacinas Atenuadas/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cytomegalovirus Vaccines); 0 (GPI-Linked Proteins); 0 (Intercellular Signaling Peptides and Proteins); 0 (Ligands); 0 (ULBP2 protein, human); 0 (Vaccines, Attenuated)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170601
[Lr] Data última revisão:
170601
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161202
[St] Status:MEDLINE
[do] DOI:10.1371/journal.ppat.1006015


  10 / 231 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27882457
[Au] Autor:Anderholm KM; Bierle CJ; Schleiss MR
[Ad] Endereço:Division of Pediatric Infectious Diseases and Immunology, Department of Pediatrics, Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota Medical School, 2001 6th Street SE, Minneapolis, MN, 55455, USA.
[Ti] Título:Cytomegalovirus Vaccines: Current Status and Future Prospects.
[So] Source:Drugs;76(17):1625-1645, 2016 Nov.
[Is] ISSN:1179-1950
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Congenital human cytomegalovirus (HCMV) infection can result in severe and permanent neurological injury in newborns, and vaccine development is accordingly a major public health priority. HCMV can also cause disease in solid organ transplant (SOT) and hematopoietic stem-cell transplant (HSCT) recipients, and a vaccine would be valuable in prevention of viremia and end-organ disease in these populations. Currently there is no licensed HCMV vaccine, but progress toward this goal has been made in recent clinical trials. A recombinant HCMV glycoprotein B (gB) vaccine has been shown to have some efficacy in prevention of infection in young women and adolescents, and has provided benefit to HCMV-seronegative SOT recipients. Similarly, DNA vaccines based on gB and the immunodominant T-cell target, pp65 (ppUL83), have been shown to reduce viremia in HSCT patients. This review provides an overview of HCMV vaccine candidates in various stages of development, as well as an update on the current status of ongoing clinical trials. Protective correlates of vaccine-induced immunity may be different for pregnant woman and transplant patients. As more knowledge emerges about correlates of protection, the ultimate licensure of HCMV vaccines may reflect the uniqueness of the target populations being immunized.
[Mh] Termos MeSH primário: Infecções por Citomegalovirus/imunologia
Infecções por Citomegalovirus/prevenção & controle
Vacinas contra Citomegalovirus/imunologia
Citomegalovirus/imunologia
[Mh] Termos MeSH secundário: Animais
Ensaios Clínicos como Assunto
Seres Humanos
Vacinas de DNA/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cytomegalovirus Vaccines); 0 (Vaccines, DNA)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161125
[St] Status:MEDLINE



página 1 de 24 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde